Second, all subjects in our study lacked PET or cerebrospinal fluid examinations to identify AD pathological biomarkers such as Aβ or tau deposition, which makes it difficult to distinguish mixed dementia. The gene discussed is MAPT; the disease is Alzheimer disease.